{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:26:18Z","timestamp":1791343578687,"version":"4.3.1"},"reference-count":41,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2004,10]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To review the pharmacology, virology, pharmacokinetics, resistance profile, clinical efficacy, safety, and drug interactions of atazanavir.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES<\/jats:title>\n                    <jats:p>A PubMed and NLMGateway search (1966\u2013June 2004) utilizing the key words atazanavir and BMS-232632 was performed. Abstracts from scientific meetings, including the Conference on Retroviruses and Opportunistic Infections, International AIDS Society Conference on HIV Pathogenesis and Treatment, Interscience Conference on Antimicrobial Agents and Chemotherapy, and the Infectious Diseases Society of America, were also reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION AND DATA EXTRACTION<\/jats:title>\n                    <jats:p>All publications and meeting abstracts were reviewed, and information relevant to the formulary decision-making process was selected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS<\/jats:title>\n                    <jats:p>Atazanavir is a once-daily protease inhibitor (PI) that received approval by the Food and Drug Administration in June 2003. In clinical trials in antiretroviral (ARV)-na\u00eeve patients, atazanavir had efficacy similar to that of efavirenz or nelfinavir. In ARV-experienced patients, atazanavir was inferior to lopinavir\/ritonavir unless atazanavir was coadministered with low-dose ritonavir. Following failure of an atazanavir-containing regimen in ARV-na\u00eeve patients, a unique I50L mutation was seen. Atazanavir resistance is likely when resistance to \u22653 PIs is present. Atazanavir can cause increases in unconjugated bilirubin levels, which rarely leads to jaundice or scleral icterus. In contrast to comparators, atazanavir did not negatively impact the lipid profile. Similar to other PIs, atazanavir is metabolized by and inhibits CYP3A at clinically relevant concentrations; therefore, many potential drug interactions exist.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Atazanavir is a once-daily PI that, unlike other PIs, does not negatively impact the lipid profile. Atazanavir may be particularly desirable in patients with hyperlipidemia or other coronary artery disease risk factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1d394","type":"journal-article","created":{"date-parts":[[2004,9,7]],"date-time":"2004-09-07T21:33:43Z","timestamp":1094592823000},"page":"1664-1674","source":"Crossref","is-referenced-by-count":40,"title":["Atazanavir"],"prefix":"10.1177","volume":"38","author":[{"given":"Joanne J","family":"Orrick","sequence":"first","affiliation":[{"name":"Joanne J Orrick PharmD BCPS, Clinical Assistant Professor, Colleges of Nursing and Pharmacy, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corklin R","family":"Steinhart","sequence":"additional","affiliation":[{"name":"Corklin R Steinhart MD PhD, Senior Attending Physician, Mercy Hospital; Steinhart Medical Associates, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2004,10,1]]},"reference":[{"key":"bibr1-aph.1D394","unstructured":"1. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. March 23, 2004. www.aidsinfo.nih.gov (accessed 2004 Mar 25)."},{"key":"bibr2-aph.1D394","volume-title":"Product information. Reyataz (atazanavir)","year":"2004"},{"key":"bibr3-aph.1D394","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.11.9.1295"},{"key":"bibr4-aph.1D394","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.8.2093-2099.2000"},{"key":"bibr5-aph.1D394","unstructured":"5. Agarwala S, Grasela D, Child M, Geraldes M, Geiger M, Meeker J,  Characterization of the steady-state pharmacokinetic (PK) profile of atazanavir beyond the 24\u2013hour dosing interval. Presented at: 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, July 13\u201316, 2003."},{"key":"bibr6-aph.1D394","unstructured":"6. O'Mara E, Cirincione B, Mummaneni V, Grasela T, Grasela D. Population pharmacodynamic assessment of the safety and antiretroviral activity of BMS-232632 (abstract A-507). Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16\u201319, 2001."},{"key":"bibr7-aph.1D394","unstructured":"7. O'Mara E, Mummaneni V, Randall D, Segali N, Olsen S, Tanner T,  BMS-232632: a summary of multiple dose pharmacokinetic, food effect, and drug interaction studies in healthy subjects (abstract 504). Presented at: 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30\u2013February 4, 2000."},{"key":"bibr8-aph.1D394","unstructured":"8. Randall D, Agarwala S, Mummaneni V, Geraldes M, Chabuel D, Russo R,  Multiple-dose pharmacokinetics of atazanavir in healthy subjects: a summary of food effect and drug interaction studies (abstract). Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 27\u201330, 2002."},{"key":"bibr9-aph.1D394","unstructured":"9. Randall D, Agarwala S, Mummaneni V, Geraldes M, Giordano M, O'Mara E. Tissue compartment concentrations of atazanavir (ATV) in cerebrospinal fluid, seminal fluid, and plasma in HIV+ subjects (abstract H-1711). Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 27\u201330, 2002."},{"key":"bibr10-aph.1D394","unstructured":"10. Agarwala S, Russo R, Mummaneni V, Randall D, Geraldes M, O'Mara E. Pharmacokinetic (PK) interaction study of atazanavir (ATV) with ritonavir (RTV) in healthy subjects. Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 27\u201330, 2002."},{"key":"bibr11-aph.1D394","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.9.2319-2326.2000"},{"key":"bibr12-aph.1D394","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.4.1324-1333.2003"},{"key":"bibr13-aph.1D394","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200305230-00021"},{"key":"bibr14-aph.1D394","doi-asserted-by":"publisher","DOI":"10.1086\/386291"},{"key":"bibr15-aph.1D394","unstructured":"15. Colonno R, Parkin N, McLaren C, Seekins D, Hodder S, Schnittman S,  Pathways to atazanavir resistance in treatment experienced patients and impact of residue 50 substitutions (abstract 656). Presented at: 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 5\u201311, 2004."},{"key":"bibr16-aph.1D394","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200301010-00004"},{"key":"bibr17-aph.1D394","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200312050-00007"},{"key":"bibr18-aph.1D394","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200408150-00003"},{"key":"bibr19-aph.1D394","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200306130-00008"},{"key":"bibr20-aph.1D394","unstructured":"20. Nieto-Cisneros L, Zala C, Fessel WJ. Atazanavir (ATV) vs lopinavir\/ritonavir (LPV\/RTV) in patients with virologic failure to a protease inhibitor (PI): 24-week results from BMS AI424-043. Presented at: 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, July 13\u201316, 2003."},{"key":"bibr21-aph.1D394","unstructured":"21. DeJesus E, Grinsztejn B, Rodriguez C, Nieto-Cisneros L, Coco J, Lazzarin A,  Efficacy and safety of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) vs. lopinavir\/ritonavir (LPV\/RTV) in patients who have experienced virologic failure on multiple HAART regimens: 48 week results from BMS AI424-045 (abstract 547). Presented at: 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 5\u201311, 2004."},{"key":"bibr22-aph.1D394","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200406010-00005"},{"key":"bibr23-aph.1D394","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199912163412501"},{"key":"bibr24-aph.1D394","unstructured":"24. O'Mara E, Randall D, Passarell J, Steinberg S, Grasela D, Cirincione B. Population pharmacodynamic assessment of atazanavir (ATV) exposure, uridine diphosphate-glucuronosyl transferase (UGT) 1A1 genotype and safety in healthy subjects (abstract A-1253). Presented at: 42nd Interscience Congress on Antimicrobial Agents and Chemotherapy, San Diego, September 27\u201330, 2002."},{"key":"bibr25-aph.1D394","unstructured":"25. Cahn P, Piliero P, Giordano M, Thiry A, Schnittman S. Atazanavir (ATV): antiretroviral efficacy in HIV-infected patients co-infected with hepatitis B and\/or C viruses (HBV, HCV) (abstract H-1730). Presented at: 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10\u201314, 2003."},{"key":"bibr26-aph.1D394","unstructured":"26. Jemsek JG, Arathoon E, Arlotti M, Perez C, Sosa N, Pokrovskiy V,  Body fat effects of atazanavir (ATV) and efavirenz (EFV) each combined with fixed dose zidovudine (ZDV) and lamivudine (3TC) (abstract LB-13). Presented at: International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, July 13\u201316, 2003."},{"key":"bibr27-aph.1D394","first-page":"L6","volume":"7","author":"Wang S","year":"2002","journal-title":"Antiviral Ther"},{"key":"bibr28-aph.1D394","unstructured":"28. Noor MA, Grasela DM, Parker RA, Chaudhari U, Tackett D, Uderman H,  The effect of atazanavir vs. lopinavir\/ritonavir on insulin-stimulated glucose disposal rate in healthy subjects (abstract 702). Presented at: 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8\u201311, 2004."},{"key":"bibr29-aph.1D394","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.00644.x"},{"key":"bibr30-aph.1D394","first-page":"231","volume-title":"AIDS therapy","author":"Murphy RL.","year":"2003","edition":"2"},{"key":"bibr31-aph.1D394","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.6.2091-2096.2004"},{"key":"bibr32-aph.1D394","unstructured":"32. Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. January 20, 2004. www.cdc.gov\/nchstp\/tb\/tb_hiv_drugs\/toc.htm (accessed 2004 Jun 15)."},{"key":"bibr33-aph.1D394","unstructured":"33. Preston S, Piliero P, O'Mara E, Mummaneni V, Randall D, Morvillo C,  Evaluation of the steady-state interaction between atazanavir (ATV) and efavirenz (EFV) (abstract 443). Presented at: 9th Conference on Retroviruses and Opportunistic Infections, Seattle, February 24\u201328, 2002."},{"key":"bibr34-aph.1D394","doi-asserted-by":"crossref","unstructured":"34. Boffito M, Kurowski M, Kruse G, Hill A, Nelson M, Moyle G,  Atazanavir enhances saquinavir hard gel concentrations in a ritonavir-boosted once daily regimen. Presented at: 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 5\u201311, 2004.","DOI":"10.1097\/00002030-200406180-00007"},{"key":"bibr35-aph.1D394","unstructured":"35. O'Mara E, Agarwala S, Randall D, Geraldes M, Stoltz R, Mummaneni V. Steady-state pharmacokinetic interaction study of atazanavir (ATV) with efavirenz (EFV) and ritonavir (RTV) in healthy subjects (abstract 444). Presented at: 9th Conference on Retroviruses and Opportunistic Infections, Seattle, February 24\u201328, 2002."},{"key":"bibr36-aph.1D394","doi-asserted-by":"crossref","unstructured":"36. Tackett D, Child M, Agarwala S, Geiger M, Geraldes M, Laura B,  Atazanavir: a summary of two pharmacokinetic drug interaction studies in healthy subjects (abstract 543). Presented at: 10th Conference on Retroviruses and Opportunistic Infections, Boston, February 10\u201314, 2003.","DOI":"10.2165\/00128413-200313780-00026"},{"key":"bibr37-aph.1D394","unstructured":"37. Prelutsky D, Salvato P, Falcon R. Pharmacokinetics of saquinavir hard gel capsule (Invirase) when combined with atazanavir (abstract 8.11). Presented at: 4th International Workshop on the Clinical Pharmacology of HIV Therapy, Cannes, France, March 27\u201329, 2003."},{"key":"bibr38-aph.1D394","unstructured":"38. Agarwala S, Mummaneni V, Randall D, Geraldes M, Stoltz R, O'Mara E. Pharmacokinetic (PK) effect of rifabutin (RIF) on atazanavir (ATV) with and without ritonavir (RTV) in healthy subjects (abstract 445\u2013W). Presented at: 9th Conference on Retroviruses and Opportunistic Infections, Seattle, February 24\u201328, 2002."},{"key":"bibr39-aph.1D394","unstructured":"39. PACTG 1020\u2013A-BMS232632 used in combination with other anti-HIV drugs in HIV-infected infants, children, and adolescents. ClinicalTrials. gov. A Service of the National Institutes of Health. www.clinicaltrials.gov\/ct\/show\/NCT00006604?order=1 (accessed 2004 Aug 17)."},{"key":"bibr40-aph.1D394","volume-title":"Drug topics red book","year":"2003"},{"key":"bibr41-aph.1D394","volume-title":"Drug topics red book update","year":"2004"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1D394","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1D394","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1D394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:07:48Z","timestamp":1777374468000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1D394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["10.1345\/aph.1D394"],"URL":"https:\/\/doi.org\/10.1345\/aph.1d394","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10]]}}}